Skip to main content

Table 2 The qualitative and quantitative demographic data of the research participants

From: Comparison of the effect of phenobarbital & levetiracetam in the treatment of neonatal abstinence syndrome (NAS) as adjuvant treatment in neonates admitted to the neonatal intensive care unit: a randomized clinical trial

Variable

Phenobarbital treatment group

Levetiracetam treatment group

P-value

Frequency

Percentage

Frequency

Percentage

Sex

     

Male

23

56.1

24

58.5

0.823

Female

18

43.9

17

41.5

Mothers age at the time of childbirth

     

25 years and lower

11

26.8

6

14.6

0.189

26–30 years

8

19.5

13

31.7

31–35 years

11

26.8

11

26.8

36–40 years

11

26.8

8

19.5

Above 40 years

0

0.0

3

7.3

Route of delivery

     

Vaginal delivery

19

46.3

14

34.1

0.260

Cesarean section

22

53.7

27

65.9

Mother’s addiction type

     

Opium

19

46.3

22

53.7

0.236

Heroin & opium

6

14.6

4

9.8

Heroin

2

4.9

2

4.9

Methadone

8

19.5

4

9.8

Buprenorphine

1

2.4

0

0.0

Crystal & opium

2

4.9

0

0.0

Opium juice & methadone

2

4.9

0

0.0

Methadone & heroin

1

2.4

3

7.3

Crystal & methadone

0

0.0

2

4.9

Heroin & crystal

0

0.0

1

2.4

Opium juice

0

0.0

2

4.9

Methadone, heroin & crystal

0

0.0

1

2.4

Mother’s addiction time

     

Lower than 12 months

1

2.4

2

4.9

0.324

12–24 months

19

46.3

23

56.1

24–36 months

7

17.1

7

17.1

36–48 months

5

12.2

7

17.1

48–60 months

7

17.1

2

4.9

Above 60 months

2

4.9

0

0.0

Gestational age (week) (mean + SD)

38.29

1.48

38.15

1.52

0.152

Finnegan score (mean + SD)

10.61

1.27

10.85

1.15

0.301

Weight at birth (gram) (mean + SD)

2733.90

344.15

2729.27

389.38

0.830